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 INTRODUCTION 
Chikungunya fever is an important arthropod-borne virus (arbo virus) 
disease.(47,48,49) Until recently it attracted only minor interest in the medical 
community and did not evoke the fear associated with other arboviruses, 
such as dengue and west nile viruses. The recent resurgence of chikugunya 
fever has drawn global attention due to its explosive onset, rapid spread, high 
morbidity and myriad clinical manifestations.(17,59,61,76,79) 
Documented first time from an outbreak in 1952(41,67). Explosive 
outbreaks of epimedics of the disease have occurred after periods of long 
quiescence in different parts of the world. After an extensive outbreak during 
the beginning of the current millenium in the French territory of Reunion 
Islands in the Indian ocean, Chikungunya fever has been reported from 
almost  40 countries from different regions of the world(88). After an interval 
of 32 years, India  witnessed a massive epidemic in 2005, which is still 
ongoing in different parts of the country(48). The disease has affected millions 
of people and left many with crippling disabilities(88).  
Chikungunya virus (CHIK V)  produces a dengue-like illness in 
humans, characterized by fever, rash, and severe arthralgia persisting for a 
few weeks to several months. The most significant characteristic of 
Chikungunya is the prolonged arthralgic syndrome that primarily affects the 
 peripheral small joints associated with excruciating pain.(61) The disease is 
generally non-fatal and the acute phase resolves within 3–4 days leaving the 
arthralgic syndrome persisting for some more time. The clinical course of the 
acute phase of infection has been well characterised during previous 
epidemics in African countries, the Indian subcontinent and Southeast 
Asia.(88)  It involves an incubation period lasting between two to six days, 
followed by the abrupt onset of fever associated with intense diffuse muscle 
and joint pain. Headache, photophobia, nausea, vomiting, diarrhea and a 
maculopapular or morbiliform skin rash may accompany these symptoms. 
Treatment is mainly symptomatic, with remission observed in most patients 
some days after the infection. 
A  human-mosquito-human cycle is responsible for the maintenance 
of the virus in the South East Asia region in contrast to the sylvatic 
transmission cycle occurring in the African continent.(88) The re-emergence 
of chikungunya fever has been attributed to a multitude of factors including 
mutation of the virus, absence of herd immunity, lack of efficient vector 
control activities and globalization and emergence of another vector, Aedes 
albopictus (A. albopictus) in addition to Aedes aegypti (A.aegypti) as an 
efficient transmitter of chikungunya virus.(88)  
Currently, the diagnosis of Chikungunya infection is accomplished 
through either virus isolation or detection of virus specific antibodies by 
 enzyme linked immunosorbent assay (ELISA) or genomic detection by RT–
PCR.(74,78) 
Although isolation is considered as gold standard, however, it is 
practically difficult, time consuming and requires live viable virus. The RT–
PCR-based molecular assays are now being increasingly utilized for rapid, 
early diagnosis particularly during acute phase of the illness. 
The re-emergence and persistence of CHIKV suggests the need for 
continuous monitoring and identification of the newly evolving variants and 
their genetic divergence with a view to plan for appropriate strategies for 
vaccine development. Further studies on the vector prevalence, the 
environmental conditions that favour the persistence of CHIKV, serosurveys 
in humans and mosquitoes in the affected areas are required to better 
understand the dynamics of Chikungunya in this region and prevent further 
spread of the virus to other parts of the country.(88) 
This study was undertaken to study the incidence, clinical presentation 
and molecular characterisation of chikungunya  virus in patients presenting 
with fever and arthralgia in Government General Hospital, Chennai. 
 
 
 
 AIMS OF THE STUDY 
1. To study the incidence of chikungunya among patients with fever in               
      Government General Hospital, Chennai. 
2.  To determine the seropositivity of chikungunya cases. 
3.  To determine the molecular characterisation of chikungunya virus. 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
Historical Background 
             There are historical accounts of epidemics of fever, 
arthralgias/arthritis and rash, resembling what is now called “Chikungunya 
fever” dating back to 1824 from India and elsewhere.(87) Chikungunya fever 
was first described in 1952,(41,67) following an outbreak on the Makonde 
Plateau, along the border between Tanganyika and Mozambique [The 
mainland part of modern day Tanzania] in the Nawala district. The 
chikunugunya  fever  was  first described by Marion Robinson and 
W.H.R.Lumsden in 1955(41). 
Etymology and History of the Name “Chikungunya” 
              For a long time, it was erroneously reported that the word 
“Chikungunya” was derived from the “Swahili” language both in lay press 
and the media and reputed medical journals(7). The word “Chikungunya” is 
derived from the Makonde language, spoken by an ethnic group in south-east 
Tanzania and northern Mozambique from the root verb “kungunyala”, 
meaning “to dry up or become contorted,” and signifies the cause of a 
contortion or folding(4,41). Literally, the word “Chikungunya” translates to 
“that which bends up” in reference to the stooped posture developed due to 
the rheumatological manifestations of the disease. In Congo, it has been 
 called “buka-buka”, meaning “broken-broken” once again reflecting the 
incapacitating arthralgias that are common acute manifestations of 
Chikungunya fever(51).  In concurrent research, Robinson glossed the 
Makonde term more specifically as "that which bends up."(41) 
Natural history and transmission 
          Chikungunya fever epidemics display secular, cyclical, and seasonal 
trends. These  epidemics are characterized by explosive outbreaks 
interspersed by periods of disappearance ranging from several years to a few 
decades. The exact reason for this behavior still remains a mystery. Several 
mechanisms including a complex interaction between various factors such as 
the susceptibility of humans and the mosquito vectors to the virus, conditions 
facilitating mosquito breeding resulting in a high vector density, ability of 
the vector to efficiently transmit the virus are all thought to play a 
role.(47,59,76) International travel has facilitated the introduction of the virus 
from endemic areas to other areas resulting in outbreaks of the illness, and 
imported cases of Chikungunya fever have been documented in France, 
Italy, Australia, and United States of America also(14,31,60,76). 
         The natural cycle of the virus is human-mosquito-human; evidence is 
available regarding the existence of epizootic cycles that may maintain the 
virus during the interepidemic period.(17,47,59,61,76,70,79)  During epidemics, 
human beings serve as the Chikungunya virus reservoirs; during 
 interepidemic periods, several vertebrates such as monkeys, rodents, birds, 
have been implied as the reservoir.  
Little is known regarding whether and how the Chikungunya virus is 
maintained in the wild in Asia. Unlike dengue virus, there is no evidence for 
transovarial transmission of Chikungunya virus in mosquitoes. Variations in 
the geographical strains of Aedes mosquitoes regarding their susceptibility to 
infection and ability to transmit the virus may be crucial factors in 
determining endemicity of Chikungunya virus in a given 
region.(17,47,59,61,70,76,79) Vertical maternal-fetal transmission has been 
documented in pregnant women affected by Chikungunya fever.(66) 
The virus 
Chikungunya virus is a Group IV positive sense single stranded RNA 
virus belonging to family Togaviridae with genus Alphavirus and species 
Chikungunya virus (CHIKV). It has a genome consisting of a linear, 
positive-sense, approximately 11.8 kb single stranded ribonucleic acid 
(RNA) molecule, a 60-70 nm diameter capsid and a phospholipid 
envelope(59,61,76).  The complete genome was found to be 11,805 nucleotides 
in length. Coding sequences consisting of two large open reading frames of 
7422 nucleotide and 3744 nucleotide encoding the non-structural polyprotein 
(2474 amino acids) and the structural polyprotein (1248 amino acids), 
respectively.  The non-structural polyprotein is the precursor of proteins 
 nsP1 (535 amino acids), nsP2 (798 amino acids), nsP3 (530 amino acids) and 
nsP4 (611 amino acids) and the structural polyprotein is the precursor of 
protein C (261 amino acids), E3 (64 amino acids), E2 (423 amino acids), 6K 
(61 amino acids) and E1 (439 amino acids)(59,61,76).  
Studies on Chikungunya virus isolates collected from various 
geographical areas indicate that three lineages with distinct genotypic and 
antigenic characteristics exist. These include the West-African; the East, 
Central, Southern African (ECSA) phylogroups that have contributed to 
epidemics in Africa; and the Asian phylogroup. Phylogenic analysis based 
on partial sequences of NS4 and E1 genes showed that isolates from India 
during the present epidemic and the isolates from the ongoing Indian Ocean 
outbreak represent a distinct clade within the ECSA phylogroup(37,47,57,90), 
while all earlier isolates from India (1963 to 1973) were Asian 
phylogroup.(32,50,56,58,74)  This finding corroborates that CHIK virus originated 
in Africa and subsequently was introduced into Asia. These different 
genotypes exhibit differences in their transmission cycles: in Asia, the virus 
appears to be maintained in an urban cycle with Aedes aegypti mosquito 
vectors, while CHIK virus transmission in Africa involves a sylvatic cycle, 
primarily with Aedes furcifer and Aedes africanus mosquitoes. Complete 
genomic sequence of CHIKV has been determined(20). 
 
 INACTIVATION BY  PHYSICAL AND CHEMICAL AGENTS 
  Chikungunya virus  is inactivated by 70% ethanol, 1% sodium 
hypochlorite, 2% glutaraldehyde, lipid solvents, moist or dry heat > 58° C, as 
well as drying.(87) 
Mutations in the Chikungunya virus genome and infectivity 
A mutation at residue 226 of the membrane fusion glycoprotein E1 
(E1-A226V- substitution of alanine at position 226 with valine) was detected 
in more than 90% of Chikungunya virus isolates from Reunion Islands after 
September, 2005. By reducing the cholesterol dependence of the virus to 
infect mosquito hosts, this mutation is postulated to have facilitated the 
replication and transmission of the virus by this mosquito.(72,83) Because 
mosquitoes often do not have enough cholesterol for viruses to efficiently 
infect the host cells, the E1:A226V mutation might have helped in 
replication and transmission of the virus. This rapid pathogen adaptation to 
ecologic perturbation appears to be a unique example of the “evolutionary 
convergence” occurring in nature.(20) 
PATHOGENESIS 
  In humans, CHIKV produces disease about 48 hours after mosquito 
bite. Patients have high viraemia during the first 2 days of illness. Viraemia 
declines around 3 or 4 days, usually disappearing by day 5.(53,74) 
 Haemagglutination inhibition (HI) and neutralizing antibodies can usually be 
detected after day 5 with fading viraemia.(53) Neuro-invasive cases and 
haemorrhagic manifestation related to CHIKV infection have been 
conclusively documented in scientific literature. "Silent" CHIKV infections 
do occur, but how commonly this happens is not yet known. CHIKV 
infection (whether clinical or silent) is thought to confer lifelong 
immunity.(87)  
Clinical laboratory findings are not remarkable. Few patients may 
present with leucopoenia with relative lymphocytosis; however, most 
patients will have normal blood count. The platelet count may be moderately 
less. Erythrocyte sedimentation rate is significantly elevated and C-reactive 
protein is positive in acute-cases.(28,49)  
Molecular pathogenesis 
Little information is available on the molecular pathogenesis of 
Chikungunya fever. Given the similarities between the two, molecular 
pathogenesis of Chikungunya fever may be similar to the observations made 
on the molecular and cellular aspects of Ross River virus (RRV) that also 
causes epidemics of fever, polyarthritis (including rheumatic symptoms), and 
mucocutaneous manifestations similar to that seen with Chikungunya 
fever.(28)  A defective cell-mediated immune response (CMI) where CD8+ T-
 lymphocytes are absent or inactive has been thought to be the cause of 
chronic disease and viral persistence. Oversecretion of toxic chemokines or 
apoptosis are postulated as causes of cell/tissue destruction and associated 
clinical symptoms.(61)   An antibody-dependent enhancement (ADE) 
mechanism similar to that suggested for dengue viruses(69)  has also been 
implicated in the pathogenesis. Cell tropism of Chikungunya virus in the 
murine brain; susceptibility of human adherent cells (epithelial and 
endothelial cells, primary fibroblasts, and macrophages) to Chikungunya 
virus whose replication induces a cytopathic effect and apoptosis;(76,78) are all 
leads that need to be studied in greater detail. Presence of viral antigen in 
muscle progenitor cells (also called muscle satellite cells) in a muscle biopsy 
from a patient who had a clinical relapse some weeks after disease onset(64,76) 
suggests the possibility of persistence of Chikungunya virus in some patients 
long after initial viremia. Further research is required in this area to clarify 
these issues. 
The vector 
 In Asia and the Indian Ocean region, Chikungunya fever is 
transmitted by the bite of mosquitoes of the genus Aedes (which also 
transmit the dengue virus). Aedes aegypti is considered to be the principal 
vector and Aedes albopictus (Asian Tiger mosquito) has also recently 
emerged as an important vector. A. aegypti predominantly breeds in stored 
 fresh water, such as desert coolers, flower vases, water-tanks, etc., and in 
peri-domestic areas (discarded household junk items like vehicular tyres, 
coconut shells, pots, cans, bins, etc.,) in urban and semiurban 
environments.(71,88) Adult mosquitoes rest in cool and shady areas and bite 
humans during the daytime. Insecticide treated bed nets are, therefore, of 
limited use against Aedes mosquitoes. The bite of only the female mosquito 
is considered to be infective because a blood meal is required for the 
formation of the egg. 
The same vectors can sometimes transmit several arboviruses, and 
mixed epidemics of Chikungunya fever and dengue fever;(15,59) Chikungunya 
fever, dengue fever, and Plasmodium falciparum malaria(86) have sometimes 
been documented. 
 ANIMAL PATHOGENECITY AND CELL/ TISSUE TROPISMS 
Pathogenicity studies of CHIKV infection could not be studied due to 
the lack of a proper animal model.  There is a recent report that explains the 
development of a mouse model and that CHIK virus replicates first  in the 
liver, and targets muscle, joints and skin, closely resembling the cell/tissue 
tropism observed in biopsy samples of CHIK infected humans. It also states 
the dissemination of virus to choroids plexuses and the leptomeninges in the 
CNS in severe infections.(18)  There was also evidence for  the presence of 
virus in the leg muscles even after the disappearance of viraemia, which 
 lasted for 6-7 days. Histopathologic studies revealed focal necrosis and 
inflammation in the skeletal muscle followed by fibrosis and distrophic 
calcification. Distrophic calcification was also observed in the joint 
cartilages.(19) 
EPIDEMIOLOGY 
Global scenario 
Following the report from Tanganyika in 1952,(41,67) Chikungunya 
epidemics have been reported from several parts of the world including 
Africa, Asia, and elsewhere. In South-East Asia, epidemics have been 
documented in India, Pakistan, Sri Lanka, Myanmar, Thailand, Indonesia, 
the Philippines, Cambodia, Vietnam, Hong Kong, and Malaysia.(5,47,59,88)  
Since 2003, there have been outbreaks in the islands of the Pacific Ocean, 
including Madagascar, Comoros, Mayotte the Seychelles, and Mauritius, and 
the Reunion Island (French overseas district in the Indian Ocean).(5)  
India 
Since the first Indian report from Kolkata (Calcutta then),(74)  several 
outbreaks of Chikungunya fever have been documented from different parts 
of India including Vellore,(30) Chennai (then called Madras) in Tamil Nadu, 
and Puducherry (then called Pondicherry),(82)  Visakhapatnam, Rajahmundry, 
and Kakinada in Andhra Pradesh,(32,47,59,88,90)  Nagpur,(68) and Barsi(56)  in 
 Maharastra. Occasional cases were recorded in Maharastra State between 
1983 and 2000.(50) Keeping with the character of the disease, Chikungunya 
fever has re- emerged in India after nearly 32 years in October 2005(47,59,88)  
and the outbreak is ongoing. 
In the investigation carried out by the National Institute of Virology(90)  
from several districts in Andhra Pradesh, Karnataka, and Maharastra (n = 
1938), the occurrence of Chikungunya epidemic was confirmed. During the 
current outbreak as per the current release by the Ministry of Health and 
Family Welfare, Government of India, 13,91,165 cases suspected to be 
Chikungunya fever have been recorded from several parts of India during the 
year 2006.(47,88) The corresponding figures for the subsequent years have 
been 59,535 cases (2007) and 71,222 (till November 2008),(47,88) and 13,117 
(till June 2009).(21) Some workers have approximated that these figures are 
underestimates and the actual figures could be up to five times these 
numbers.(45)  
Clinical Manifestations 
Acute stage 
Chikungunya fever affects all age groups, and both genders are 
equally affected. The incubation period ranges from 3 to 12 days (usually 3-
7 days). In susceptible populations, the attack rates can be as high as 40-
85%(17, 47,59,61,76,79)  
 Onset 
Prodromal symptoms are rare. In the acute stage, the onset is usually 
abrupt and sudden with high-grade fever (usually 102-105 °F), severe 
arthralgias, myalgias, and skin rash.(17,47,59,61,76,79) Headache, throat 
discomfort, abdominal pain, and constipation may also be evident. 
Conjunctival congestion,  persistent conjunctivitis, cervical, or sometimes 
generalized lymphadenopathy may be present. 
Mucocutanoeus Manifestations 
Several mucocutaneous manifestations, such as morbilliform eruption, 
scaling, macular erythema, intertrigo, hypermelanosis, xerosis, excoriated 
papules, urticaria, and petechial spots have been described in patients with 
Chikungunya fever.(3,29)  
Arthropathy 
The Chikungunya viral polyarthropathy frequently involves the small 
joints of the hand, wrist, and ankles and the larger joints such as knee and 
shoulder; more than ten joint groups may be involved.(17,59,61,75,76,79)  Axial 
involvement is common. The joints are swollen and the involvement can be 
asymmetric sometimes; disabling acute tenosynovitis is frequently 
present.(17,59,61,79)  Sometimes, atypical features such as Baker's cyst may be 
present. Sometimes sternoclavicular and temporomandibular joints may be 
 involved; hips are relatively spared.(8,75,76) Swollen tender joints and 
crippling arthritis are usually evident  in almost all the patients at 
presentation. The pain may be severe enough to immobilize the patient and 
interfere with sleeping in the night. Joint pain may worsen with movement 
and back ache may also be present. Radiological findings are usually normal, 
and biological markers of inflammation may be normal or moderately 
elevated.(24,34)  
Effect on pregnancy 
Chikungunya fever appears to have a direct impact on pregnancy with 
a higher risk of abortion in the first trimester and mother-to-child 
transmission in the last trimester.(17,59,61,76,79)   In a study from the Reunion 
Islands outbreak, three out of nine miscarriages before 22 weeks of gestation 
were attributed to the Chikungunya virus infection documented by positive 
reverse transcription polymerase chain reaction (RT-PCR) in amniotic 
fluid.(38)  
Others 
Several neurological, ocular, and hemorrhagic manifestations of 
fulminant hepatitis have been documented during the recent epidemic.(22) 
Other uncommon manifestations include myocarditis after acute febrile 
 illness,(54,55) mixed cryoglobulinemia in the first months after disease onset, 
and long persistence of symptoms.(76)  
Course of the Disease 
The fever is usually of short duration and usually resolves in 3 to 4 
days. In some patients, a biphasic pattern of fever has been described with a 
febrile episode of 4 to 6 days, followed by a fever-free period of a few days 
followed by recurrence of fever (usually 101-102 °F) that may last a few 
days.(76) 
Chronic stage 
In a majority of the patients, the joint pains resolve in 1 to 3 weeks. 
However, the arthritis can persist in about 33% of patients for 4 months, 
15% for 20 months, and in 12% for 3-5 years.(12,24,34,59) The chronic stage is 
characterized by unpredictable relapses that include sensation of fever, 
asthenia, and exacerbation of arthralgias and stiffness. Affected patients may 
manifest inflammatory polyarthritis, severe subacute tenosynovitis/bursitis 
(consequently nerve tunnel syndromes) in hands, wrists, and exacerbation of 
pain on movement in previously injured joints.(75,76)  Older individuals and 
those with underlying rheumatic and traumatic joint disorders seem to be 
more vulnerable to develop the chronic stage.(17,59,61,76,79)  Rarely, rheumatic 
manifestations resulting in joint destruction before resolution after 15 years 
 have been reported.(13)   Some studies have documented occurrence of 
rheumatoid arthritis following Chikungunya fever, suggesting that the viral 
infection may have a role in the initiation or unmasking of rheumatoid 
arthritis.(10)  
Chikungunya Fever in Neonates and Children 
Neonates 
Mothers afflicted with Chikungunya fever in the perinatal period (−4 
days to +1 days) can transmit Chikungunya fever to neonates by vertical 
transmission.(73) Intrapartum transmission also contributes; caesarean section 
does not appear to prevent the transmission.(26,73,76)  Neonatal Chikungunya 
fever is associated with fever, poor feeding, pain, distal edema, various skin 
manifestations, seizures, meningoencephalitis, and echocardiographic 
abnormalities in the newborn.(73,76)  
Children 
Chikungunya fever in children resembles that observed in adults with 
important differences.(73)  Common clinical manifestations include abrupt 
onset of high-grade fever, skin rashes, minor hemorrhagic manifestations, 
arthralgia/arthritis, lymphadenopathy, conjunctival congestion, swelling of 
eyelids, and pharyngitis. Rare clinical features include neurological 
manifestations including seizures, altered level of consciousness, blindness 
 due to retrobulbar neuritis, and acute flaccid paralysis. Rheumatological 
manifestations are somewhat less frequent in children. Pediatric subjects 
may also experience febrile seizures, vomiting, abdominal pain, and 
constipation.(40,73)  
Cardinal Features Observed in the Current Epidemic in India 
Majority of the patients had presented with fever, arthralgias, arthritis, 
and mucocutaneous manifestations. In addition to these series(2,33,36,40,47,80), 
several rare manifestations  such as neurological, ocular and haemorrhagic 
manifestations have also been documented in other publications from India. 
Hemorrhagic manifestations 
Unlike dengue fever, hemorhhagic manifestations are uncommon in 
Chikungunya fever. When present, they are mild and more frequently 
encountered in Asian compared with African patients.(17,59,61,76,79)  When 
present, these manifestations include epistaxis, bleeding from the gums, 
positive Hess test, subconjunctival bleed, and petechial/purpuric rash. 
Others 
Sudden sensorineural hearing loss(6) and hypokalemic periodic 
paralysis(63) are other rare manifestations that have been reported. Severe 
systemic disease with multiple organ system involvement has also been 
observed during the recent epidemic.(81)  
 Economic Impact 
In India, the national burden of Chikungunya was estimated to be 
25,588 disability adjusted life years (DALYs) lost during 2006 epidemic, 
with an overall burden of 45.26 DALYs per million (range 0.01 to 265.62 
per million in different states). Persistent arthralgia was found to account for 
69% of the total DALYs. The productivity loss in terms of income foregone 
was estimated to be a minimum of Rs. 391 million. The actual loss is thought 
to be substantially higher than these estimates.(65)  
Differential Diagnosis 
Chikungunya fever has to be distinguished from the dengue fever 
which has the potential for much worse outcomes including death. The two 
diseases can often occur together in the same patient. Observations from 
previous outbreaks in Thailand and India, have characterized the principal 
features distinguishing chikungunya from dengue fever. In the former, shock 
or severe haemorrhage is not observed. The onset is more acute and the 
duration of fever is much shorter in chikungunya fever. In chikungunya 
fever, maculopapular rash is more frequent than in dengue fever.  In 
chikungunya fever leucopenia is more frequent than dengue fever. In dengue 
fever thrombocytopenia is more frequent than chikungunya fever. In the 
early stage when rash is absent, malaria has to be ruled out. With rash, 
measles or German measles need to be ruled out. Differential diagnosis with 
 other arthropod borne viruses of the Alphavirus genus (Ross River, Barmah 
Forest, o’nyong nyong, Sindbis, and Mayaro viruses) is difficult, but these 
are comparatively rare.(87) 
Laboratory Diagnosis of Chikungunya Fever:  
As the clinical manifestations of chikungunya fever resemble those of 
dengue and other fevers caused by arthropod borne viruses of the Alphavirus 
genus, laboratory confirmation is critical to establish the diagnosis. 
Types of Laboratory tests available and specimens required: 
Three main laboratory tests are used for diagnosing chikungunya fever: 
1. virus isolation,  2.  serological test and  3.  molecular technique of 
Polymerase Chain Reaction (PCR).   
Specimen is usually blood or serum but in neurological cases with meningo-
encephalitic feature, CSF (cerebro-spinal fluid) may also be sent. 
Virus isolation 
Virus isolation is the most definitive test. Between 2-5 ml of whole 
blood is collected during the first week of illness in a  heparinized tube and 
transported on ice to the laboratory. The isolation of CHIKV is 
comparatively more simple and effective owing to the highly cytopathic and 
fast-growing nature of the virus, which will grow to very high titers.(74)  
CHIKV replicates in various cell lines, including insect cells, for example, 
 C6/36 and other non human cell lines such as , Vero, chick embryo 
fibroblast-like cells, BHK21, L929  and human cell lines, for example, 
HeLa, MRC5 and Hep-2 cells  in which it will often induce a significant 
cytopathic effect. Human epithelial and endothelial cells, primary fibroblasts 
and, to a lesser extent, monocyte-derived macrophages, are susceptible to 
infection and permit viral production. By contrast, CHIKV does not replicate 
in lymphoid and monocytoid cell lines, primary lymphocytes and 
monocytes, or monocyte-derived dendritic cells.(28)  However, the isolation 
process is time-consuming and the degree of success is dependent on a 
number of complicating factors, for example, time of collection, 
transportation, maintenance of cold chain, storage and processing of 
samples.The cytopathic effects must be confirmed by CHIK specific 
antiserum and the results can take  between 1-2 weeks. Virus isolation must 
only be carried in BSL-3 laboratories to reduce the risk of viral transmission. 
RT-PCR.  
A specimen for PCR is heparinized whole blood. Recently, a reverse 
transcriptase, RT- PCR technique for diagnosing CHIK virus has been 
developed using nested primer pairs amplifying specific components of three 
structural gene regions, Capsid (C ), Envelope E-2 and part of Envelope E1 . 
PCR results can be available in 1-2 days. RT-PCR is also a confirmatory test 
for isolated virus.(14) 
 Serological diagnosis 
For serological diagnosis, serum obtained from 10-15 ml of whole 
blood is required. An acute phase serum must be collected immediately after 
the onset of illness and the convalescent phase serum 10-14 days later. The 
blood specimen is transported at 4 degrees Celsius and not  frozen for 
immediate transfer to the laboratory. Only if the testing cannot be done 
immediately, the serum specimen should be separated and then stored and 
shipped frozen. Serologic diagnosis can be made by demonstration of  four-
fold rise in antibody titre in acute and convalescent sera or by demonstrating 
IgM antibodies specific for CHIK virus. A commonly used test is the 
Immunoglobulin M Antibody (IgM) capture enzyme-linked immunosorbent 
assay (MAC-ELISA). Results of MAC-ELISA can be available within 2-3 
days. Cross-reaction with other flavivirus antibodies such as O’nyong-nyong 
and Semliki Forest occur in the MAC-ELISA. The later viruses are relatively 
rare in South East Asia and if further confirmation is required by ruling these 
viruses out, it can be done by neutralization tests and Hemagglutination 
Inhibition Assay (HIA). Haemagglutination inhibition antibodies appear with 
the cessation of viraemia. All patients will be positive by day 5-7 of illness. 
Neutralization antibodies parallel HI antibody.(48,61) The CHIK antigen for HI 
Test is available from NIV, Pune. 
 
 Interpretation of results: 
Sero-diagnosis rests on demonstrating a four-fold increase in CHIK 
IgG titre between the acute and convalescent phase sera. However, getting 
paired sera is usually not practical. Alternatively, the demonstration of IgM 
antibodies specific for chikungunya virus in acute-phase sera is used in 
instances  where paired sera cannot be collected. A positive virus culture 
supplemented with neutralization is taken as the definitive proof for the 
presence of chikungunya virus. Positive PCR result for E1 and C genome 
either  singly or together  from  the specimen (serum, cerebro-spinal fluid, 
etc) also constitutes a positive evidence of chikungunya virus infection.(52)  
MANAGEMENT 
Treatment of Chikungunya fever is nonsteroidal symptomatic and 
supportive. Adequate fluid intake must be ensured. Paracetamol or anti-
inflammatory drugs (NSAIDS) may be used for symptom relief. Aspirin 
should be avoided due to its effect on platelets. In a recently conducted 
double-blind, placebo-controlled, randomized trial(19)  assessing the efficacy 
of chloroquine in patients with acute Chikungunya fever, the authors(19)  
suggested that there was no justification for the use of chloroquine to treat 
acute Chikungunya infection. 
Published evidence does not support the use of corticosteroids, 
antibiotics, or antiviral drugs in the management of Chikungunya fever, and 
 indiscriminate use of these agents can be hazardous. Electrolyte imbalance, 
pre-renal acute renal failure and bleeding manifestations should be watched 
carefully and managed accordingly.(47) The optimal treatment strategy for 
viral arthropathy of Chikungunya fever is not known. Further randomized 
controlled studies with a large sample size are required to clarify the role of 
chloroquine/ hydroxychloroquine  in  the  treatment  of  Chikungunya 
arthropathy. 
Mortality 
Observations from the earlier epidemics including the experience from 
India till mid-1970s indicate that Chikungunya fever is a self-limiting 
disease; mortality was not documented. The official figures in the current 
release(21) and earlier releases by the Ministry of Health and Family Welfare, 
Government of India,(21,47,49)  also do not document mortality due to 
Chikungunya. However, there have been reports of mortality due to 
Chikungunya fever during the present epidemic in some 
publications.(1,44,45,85) Mavalankar et al.(44) compared the mortality rates in 
2006 with those in 2002-2005 for Ahmedabad and found that 2,944 excess 
deaths occurred during the Chikungunya epidemic (August-November 2006) 
when compared with the average number of deaths in the same months 
during the preceding 4 years. These authors(44)  suggested that the excess 
deaths were attributable to this epidemic. Indiscriminate use of 
 corticosteroids, NSAIDS (especially aspirin), and antibiotics which 
contribute to thrombocytopenia, gastrointestinal bleeding, nausea, vomiting, 
and gastritis. This may lead to dehydration, pre-renal acute renal failure, 
dyselectrolytemia, and sometimes hypoglycemia. These can indirectly 
contribute to the mortality due to Chikungunya fever.(47)  
Prevention 
Patients with Chikungunya fever should be advised to avoid being 
bitten by mosquitoes as the disease can be transmitted to others. Personal 
protection measures such as applying insect  repellents to the exposed skin 
can keep out A.aegypti.  Insect repellents containing  30% N,N- Diethyl-m -
Tolumide (DEET) have shown to provide an average of five hours of 
complete protection against A.aegypti after a single application on a exposed 
skin. However,in field conditions, perspiration, rain and raising temperature 
may make DEET less effective.(19) 
VACCINES 
Presently no commercial vaccine is available for Chikungunya fever 
in India, although some candidate vaccines are being tested in human beings. 
The widespread geographic distribution and recurrent epidemics causing 
severe morbidity have necessitated the need for an efficient vaccine. Levitt et 
al (1986) reviewed the developments in vaccine development taken place 
 through sixties and early 1970s.(39) Among the many preparations, the cell 
culture based formalin inactivated vaccine developed by Harrison et al 
(1971) was the most promising as it elicited high levels of neutralizing 
antibody in human volunteers in a phase 1 trial. The study also demonstrated 
excellent immunogenic response without showing any side effects or 
untoward reactions in the vaccinees making it an ideal candidate for future. 
Edelman et al (2000) pursued the work and developed an attenuated vaccine 
by serial passaging  in MRC-5 cell line. The vaccine was highly 
immunogenic and well within the tolerable limits.(23,39)  In the phase II safety 
and immunogenicity study the investigators observed sero-conversion in 
98% of the vaccinees by day 28 and the presence of N-antibodies in 85% 
volunteers for 12 months. Attempts are being made to revive the project by 
the US Army Medical Research Institute for Infectious Diseases on a request 
from the French government after the 2005-06 epidemic.(61)  
Vector surveillance and control 
Vector surveillance and control is a key element in containing 
Chikungunya fever epidemics. This can be done by active involvement of 
community and public health authorities with regard to hygiene and 
mosquito control measures is essential to stand a chance in the war against 
the mosquitoes.(76)  
 
 Future Directions 
Chikungunya fever is emerging as a global disease. Several issues 
related to Chikungunya fever, such as, the reason(s) for the mysterious 
behavior of dramatic outbreaks interspersed by periods of prolonged 
absence; virus survival in nature and factors triggering outbreaks; reasons for 
ECSA strain replacing the Asian strain during the current epidemic, among 
others, need to be further studied. The quest for an effective vaccine is still 
on.(87) 
 
 
 
 
 
 
 
 
 
 MATERIALS   AND   METHODS 
PLACE OF STUDY 
The study was conducted at the Institute of Microbiology, Madras 
Medical College and Government General Hospital, Chennai in association 
with the fever outpatient clinic. Samples collected were processed at the 
Institute of Microbiology, Chennai and molecular diagnostic study was done 
at the Department of Virology, King Institute of Preventive Medicine, 
Chennai. 
STUDY PERIOD 
The cross sectional study was conducted from  October 2009 to  
September 2010. 
SAMPLE 
Blood samples from 150 patients with clinical features suggestive of 
Chikungunya fever were included in this study. The samples were collected 
aseptically and serum was separated  and stored at -70ºC. 
 
 
 
 INCLUSION CRITERIA 
The following patients were included in this study. 
• Patients who had sudden onset of fever, rash, joint pain, chills, 
headache, nausea, vomiting, low back pain, conjunctival  congestion 
and abdominal pain. 
• All age groups .    
• Both males and females. 
EXCLUSION CRITERIA 
Patients with known history of chronic osteoarthritis, autoimmune 
diseases like rheumatoid arthritis, Systemic Lupus Erythematoses and any 
history of previous surgery of the joints were excluded. 
 
 CASE DEFINITION 
Though case diagnosis can only be made by laboratory means, 
• Chikungunya should be suspected when epidemic occurs with the 
characteristic  triad  of fever, rash and joint manifestations. 
• The  chikungunya case definition here is adapted from that proposed 
by the European Centre for Disease Control (ECDC). 
 
 
 Clinical criteria: 
• Acute onset of fever >38.5°C. 
• Severe arthralgia/arthritis not explained by other medical conditions. 
Epidemiological criteria:  
• Residing or having visited epidemic areas, 
• Having reported transmission within 15 days prior to the onset of 
symptoms 
Laboratory criteria:  
At least one of the following tests in the acute phase: 
• Virus isolation. 
• Presence of viral RNA by RT-PCR. 
• Presence of virus specific IgM antibodies in single serum sample 
collected in acute or convalescent stage. 
• Four-fold increase in IgG titres in samples collected at least three 
weeks apart. 
On this basis, cases are to be categorized as 
Possible case:   A  patient meeting  the clinical criteria 
Probable case:  A  patient meeting both the clinical and epidemiological 
criteria 
Confirmed case:  A  patient meeting the laboratory criteria, irrespective of 
the clinical presentation. 
 SOURCE OF SAMPLE 
The samples were collected from fever clinic and from in- patients 
with features suggestive of chikungunya fever at Madras Medical College 
and General Hospital, Chennai - 3. 
ETHICAL CONSIDERATIONS 
Written consent to participate in the study was obtained from the 
subjects or their guardians  after the full explanation of the study was 
provided to them. The study was reviewed and approved by Institutional 
Ethical Committee, Madras Medical College and General Hospital, Chennai-
3. All data were handled confidentially and anonymously. 
STATISTICAL ANALYSIS 
The proportional data of this cross-sectional study was tested using 
Pearson′s Chi-Square (X2) analysis test, Two sample binomial proportion 
test, Stastical analyses were carried out using Statistical Package for Social 
Sciences (SPSS) and Epi-Info softwares. 
METHODS 
The samples were subjected to IgM capture ELISA for chikungunya ,                     
Macroscopic Slide Agglutination Test for Leptospirosis, Standard 
Diagnostics(SD) Rapid immunochromatographic   Duo Cassette method for 
 Dengue at Institute of Microbiology, Madras Medical College and General 
Hospital, Chennai. Reverse Transcriptase PCR (RT-PCR) for Chikungunya 
was done for 40 samples at Department of Virology at King Institute of 
Preventive Medicine, Guindy, Chennai.  
COLLECTION, STORAGE AND TRANSPORTATION OF 
SAMPLES: 
Proper collection, processing, storage and transportation of the 
specimens are an essential aspect of the laboratory diagnosis.  
Collection of samples for isolation & molecular diagnosis 
Sample: Serum, or plasma or whole blood (in heparinized tube). 
Time of collection: Within first five days of illness 
To collect serum: 
• Aseptically collect 4-5 ml of venous blood in a tube or a vial. 
• Allow blood to clot at room temperature, centrifuge at 2000 rpm to 
separate serum. Collect the serum in a clean dry vial. 
• Use adhesive tape marked with pencil, indelible ink, or a typewritten 
self adhesive label to identify the container. The name of the patient, 
identification number and date of collection must be indicated on the 
label. 
 • All clinical samples should accompany the clinical information as per 
the proforma. 
Sample: Blood in plain vial / serum 
Time of collection: 
1st sample: 5 days after the onset of symptoms for IgM detection as these 
Antibodies appear at this time. 
2nd sample: At least 7 to 14 days after the first sample or, in the event of 
fatality, at the time of death. 
Other types of specimen for laboratory investigation: 
Specimens: CSF in meningo-encephalitis cases. 
Synovial fluid in arthritis with effusion. 
Autopsy tissues - liver, spleen, lymph nodes and thymus. 
Mosquitoes collected in nature. 
Transportation of samples 
• Transport specimens to the laboratory at 2 –8 0 C (ice box) as soon as   
possible. 
• Do not freeze whole blood, as haemolysis may interfere with serology 
test results. 
 • If more than 24-hour delay is expected before specimens can be 
submitted to the laboratory, the serum should be separated and stored 
at refrigerated temperature. 
• Samples for virus isolation and molecular diagnosis should always be 
stored and transported frozen. 
CHIKUNGUNYA ANTIBODY ELISA 
REQUIREMENTS 
1. Anti-Human IgM coated microwells(Assay plates) 
2. Chikungunya antigen. 
3. Biotinylated Anti-Chikungunya Monoclonal Antibody: (CHIK-B) 
4. Positive Controls and Negative controls 
5. Avidin-HRP(Horse- Radish Peroxidase) 
6. Wash  Buffer Concentrate(10X) 
7. Sample Dilution Buffer 
8.  Tetramethyl benzidine (TMB ) 3,3′, 5,5′- the substrate, tetramethyl 
benzidine, hydrogen peroxide in a citric-acid citrate buffer (pH 3.5-
3.8) 
9. 1N  H2 SO4 –Stop solution. 
 
 
 Chikungunya-IgM Capture ELISA 
Principle of the test 
IgM antibodies in the patient′s blood are captured by Anti-human IgM 
that are coated on to the solid surface (wells). In the next step, CHIK antigen 
is added which binds to capture IgM, if the IgM and antigen are homologus. 
Unbound antigen is removed during the washing step. In the subsequent step 
Biotinylated Anti- Chikungunya Monoclonal Antibody (CHIK-B) is added 
followed by  Avidin-HRP. Subsequently, substrate /chromogen is added and 
watched for the development of colour. The reaction is stopped by 1N 
H2SO4. The intensity of the colur /optical density is monitored at 450nm. OD 
readings are directly proportional to the amount of Chikungunya virus 
specific IgM antibodies in the sample.  
Procedure 
Serum predilution 
1. The PC, NC and CO and patient samples were diluted using suitable 
test tubes  or microtitre plate. 
2. 990 µl of serum diluents wass added to 10µl of serum and mixed well 
to get  1:100 dilution. 
 
 
 Wash Buffer Concentrate 
120ml of wash buffer concentrate was provided with each kit. Before 
use, wash buffer concentrate was diluted to get 1:10 dilution by adding 9 
parts of distilled water to 1 part of concentrate. For assay of eight samples 
100 ml of diluted wash buffer was needed. 
ELISA PROCEDURE 
1. The  sample was diluted 1:100 with sample dilution buffer. 
2. The coated microtitre wells were washed thrice with wash buffer. 
3. 50µl of diluted samples were transferred to the appropriate wells. 
4. 50 µl of Positive Control and Negative Control were transferred to the 
respective wells. 
5. The plate was kept in a humidified box (A bread box with a soaked 
cotton or tissue paper) and incubated the plate at 370 C for one hour. 
6. At the end of incubation, the plate was washed for five times with 
wash buffer. The plate was tapped after the last wash on a tissue 
paper. 
7. 50 µl of CHIK antigen was added to each well and incubated the plate 
at 370 C for one hour and the plate was washed for five times with 
wash buffer. 
 8. 50 µl of CHIK-B was added to each well and incubated the plate at 
370 C for one hour and  the plate was washed for five times with wash 
buffer. 
9. 50 µl of Avidin-HRP was added to each well and incubated the plate 
at 370C for half an hour and the plate was washed for five times. 
10. 100 µl of substrate (TMB/H2O2) was added to each well. The plate 
was incubated in dark at room temperature for 10 minutes. Observed 
for the development of colour. The reaction was stopped with 100 µl 
of1N H2SO4. 
11. The absorbance was measured at 450 nm within 10 minutes on a 
spectrophotometer. 
INTERPRETATION OF THE RESULTS 
The test was considered to be valid if  
Positive OD values ≥ 0.5 
Negative OD value ≤ 0.18 
The sample was considered as positive, if OD value of the sample tested                  
exceeds OD value of Negative control by a factor 2.1, (Sample OD ≥ 
Negative OD  x2.1)  
 
 
 
 REVERSE  TRANSCRIPTASE  POLYMERASE CHAIN REACTION   
(RT-PCR) 
PRINCIPLE 
Polymerase chain reaction (PCR) allows the exponential copying of 
part of a DNA molecule using a DNA polymerase enzyme that is tolerant to 
elevated temperatures. 
1. mRNA is copied to cDNA by reverse transcriptase using an oligo dT 
primer (random oligomers may also be used. A PCR mix is then set up 
which includes a heat-stable polymerase (such as Taq polymerase), 
specific primers for the gene of interest, deoxynucleotides and a 
suitable buffer. 
2. cDNA is denatured at more than 90 degrees (~94 degrees) so that the 
two strands separate. The sample is cooled to 50 to 60 degrees and 
specific primers are annealed that are complementary to a site on each 
strand. The primers sites may be up to 600 bases apart but are often 
about 100 bases apart, especially when real-time PCR is used.  
3. The temperature is raised to 72 degrees and the heat-stable Taq DNA 
polymerase extends the DNA from the primers.  Four cDNA strands 
(from the original two) is obtained. These are denatured again at 
approximately 94 degrees.  
 4. Again, the primers are annealed at a suitable temperature (somewhere 
between 50 and 60 degrees). 
5. Taq DNA polymerase binds and extends from the primer to the end of 
the cDNA strand. There are now eight cDNA strands.  
6. Again, the strands are denatured by raising the temperature to 94 
degrees and then the primers are annealed at 60 degrees. 
7. The temperature is raised and the polymerase copies the eight strands 
to sixteen strands. 
8. The strands are denatured and primers are annealed. 
9. The fourth cycle results in 32 strands. 
10. Another round doubles the number of single stands to 64. Of the 32 
double stranded cDNA molecules at this stage, 75% are the same size, 
that is the size of the distance between the two primers. The number of  
cDNA molecules of this size doubles at each round of synthesis 
(exponentially) while the strands of larger size only increase 
arithmetically and are soon a small proportion of the total number of 
molecules. 
After 30 to 40 rounds of synthesis of cDNA, the reaction products are 
usually analyzed by agarose gel electrophoresis. The gel is stained with 
ethidium bromide. 
 
 PROCEDURE 
  Selected samples, subjected to RT PCR as well as isolation in  C6/36  
cell line and the results evaluated. Standard RT-PCR using primers targeting 
E2 gene of  ECSA phylogroup  was performed.    
Primer Table: 
Primer details: Genomic Position 
Forward Primers: 
TATCCTGACCACCCAACGCTCC 
Reverse primers: 
ACATGCACATCCCACCTGCC 
9403-9424 
 
9693- 912 
 
RNA was extracted using QIA amp Viral RNA mini kit according to 
manufacturer’s instruction (Qiagen, UK). A one step RT- PCR test was done 
using Superscript III one step RT-PCR platinum - Taq kit (Invitrogen, UK). 
A 25 µl volume reaction was used containing 12.5 µl 2X reaction mix, 10 µl 
water, 0.2 µM (primer Table) primers, 0.5 µl RT/Taq and 1 µl extracted 
RNA. The thermo cycling conditions were 50◦c for 30 min, 94◦c for 2 min, 
40 cycles of 94◦C 15 seconds, 55◦c for 30 seconds and 68◦C for 2 min and 20 
seconds with a final extension at 68◦C for 5 minutes and final cooling step 
4◦C for 30 seconds. 
The Amplication product was 305 bp within gene that codes for the 
viral envelope protein E2. 
 MACROSCOPIC  SLIDE  AGGLUTINATION TEST  (MSAT)  
PRINCIPLE: 
MSAT is a slide agglutination test which uses formalinised and heat 
killed antigen from leptospires(L.)  belonging to different serovars 
commonly prevalent in around Chennai. The different serovars used were  
L.ictero haemorrhagiae, 
L.australis , L.autumnalis, L.griphotyphosa, L.hebdomadis, L.pomona, 
L.patoc, L.javanica and L.sejroe. 
PROCEDURE 
One drop of (5µl) antigenic suspension was mixed with equal amount 
of serum both neat and diluted; on a depression slide and rotated on a slide 
rotator at 180 rpm for 4 minutes. It was examined macroscopically, for the 
presence of agglutination. Positive and negative controls were included. 
 
 
 
 
 
 INTERPRETATION OF RESULTS 
 
A 4+ agglutination titre was indicative of recent infection and considered  
significant. 
 
1. RAPID DENGUE DUO IMMUNOCHROMATOGRAPHIC  
CASSETTE METHOD   
The Standard cassette contains a square well for addition of buffer 
solution,  a  circular well for serum sample  and  a  lateral  flow membrane  
with colloidal  gold   complexes  containing recombinant dengue 1-4 
antigens and a control. 
Principle of the test 
 If dengue specific IgM & IgG antibodies are present in the patients 
sample, they bind to Anti-human IgM or  IgG antibodies immobilized in two 
1  Clumps of agglutination with complete clearing of  
 leptospiral antigen suspension 
4+ 
2  Obvious agglutination but partial clearing of suspension  3+ 
3  50% agglutination 2+ 
4  25% agglutination 1+ 
5   No agglutination and uniformity of serum antigen   
mixture 
Negative
 lines across the cassette membrane. Colloidal  gold complexes containing 
recombinant  dengue 1-4 antigens are captured by the bound patient′s IgM or 
IgG to give visible pink lines. A control is included to indicate that the assay 
has been performed correctly. 
 Serological sensitivity of the test  - 96.3% 
Serological specificity of the test  - 95%  
Procedure 
1. 10µl of whole blood, serum or plasma was added to the circular well 
in the cassette using a micropipette. 
2. The sample was allowed to absorb entirely into the specimen pad in 
the circular well. 
3. The buffer (Phosphate buffer saline) bottle was held vertically and 
1cm above the square well, adjacent  to the circular well  in the 
cassette and 2 drops of  buffer was added. 
4. The result was read exactly 15 min after adding the buffer to the 
cassette. 
5. Any trace of a pink line in the test area indicated a positive result. 
6. Any results read after 15 min considered invalid and repeated.  
 
 Interpretation of results 
Interpretation should be based on the combined results of the IgG and IgM 
test lines. 
C  - Control line                   
M - IgM test line        
G - IgG test line 
Primary infection 
• Pink bands  in the IgM & control regions 
• The test was positive for IgM antibodies and is suggestive of  primary                       
dengue infection. 
Secondary infection   
1. Pink bands in IgM, IgG and control regions.  
The test was positive for IgM & IgG antibodies and was suggestive of 
secondary dengue infection. 
2. Pink band in IgG and control regions. 
The test was positive for IgG antibodies and was suggestive of 
secondary dengue infection.    
Negative 
• A pink band in the control region only. 
• No detectable IgG or IgM antibodies to dengue. 
Invalid 
• No pink band  in control region. 
 RESULTS 
Total number of samples tested: 150 
• Chikungunya – IgM capture ELISA, SD rapid 
immunochromatographic cassette method for Dengue, MSAT for 
Leptospira were done for the samples at Institute of Microbiology, 
Madras Medical College & Government General Hospital, Chennai. 
• Reverse  Transcriptase PCR  (RT-PCR) was done for 40 samples at 
Institute of Virology, King Institute of Preventive Medicine, Chennai. 
• Clinical data was collected for all the patients. 
TABLE - 1 INCIDENCE RATE OF CHIKUNGUNYA 
Total number of 
fever cases 
Suspected 
number of 
cases 
Chikungunya 
positive cases Incidence 
12477 150 62 0.49% 
 
       Incidence rate = 62 /12477×100= 0.49% 
       (0.38 % to 0.60 %) with 95% confidence interval  
       Burden of the disease = 1 out of 102 patients 
 
    
 
  
TABLE - 2    SEROPOSITIVITY OF CHIKUNGUNYA 
Total number of suspected 
cases 
Total number of positive 
cases Percentage 
150 62 41.33% 
    
Seropositivity  = 41.33%  (Range =35-48%)  with 95% confidence interval 
 
 
TABLE - 3  AGE DISTRIBUTION OF CHIKUNGUNYA CASES 
(n=62) 
Age group Total cases Positive cases Percentage 
0-20 years 30 7 23.3 
21-40 years 70 34 48.5 
41-60 years 47 20 42.5 
61-80years 3 1 33.3 
 
Age group 21-40 years was commonly involved in both sexes. 
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
TABLE - 4  SEX DISTRIBUTION OF CHIKUNGUNYA CASES 
Sex Total cases Positive cases Percentage 
Males 59 23 37.1 
Females 91 39 62.9 
Total 150 62 100.0 
 
TABLE - 5 PRESENTING CLINICAL FEATURES (n=62) 
Sl.no Clinical features Number of patients Percentage of patients 
1 Fever 60 96.7 
2 Arthralgia 62 100 
3 Joint swelling 47 75.8 
4 Rash 37 59.7 
5 Itching 33 53.2 
6 Conjunctival congestion 21 33.9 
7 Cough 5 8 
8 Vomiting 3 4.8 
Arthralgia was  a presenting feature in  all the cases. Other than Arthralgia, 
fever and joint swelling  were the other  predominant  symptoms followed by 
rash. 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
TABLE - 6  PLATELET COUNTS  IN CHIKUNGUNYA CASES 
(n=62) 
Platelet count 
(lakhs/cu.mm) Total number of cases Percentage 
50,000-1,00,000 5 8 
1,00,000-1,50,000 27 43.5 
>1,50,000 30 48.3 
 
92.0 % of the patients had  a platelet count of more than one lakh/ cu.mm. 
 
TABLE - 7 DISTRICTWISE DISTRIBUTION OF CHIKUNGUNYA 
CASES (n=62) 
Sl.no Districts Number of patients Percentage of patients 
1 Chennai 43 69.3 
2 Tiruvallur 5 8 
3 Kancheepuram 4 6.4 
4 Vellore 10 16.1 
 
69.3% of the chikungunya cases were from Chennai. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE - 8 ANTIBODY RESULTS IN EARLY AND LATE FEBRILE 
PERIOD (n=62) 
Sl.no Duration of fever IgM ELISA positive cases Percentage 
1 1 -5 days  8 12.9 
2 6-10 days  39 62.9 
3 More than 10 days  15 24.2 
   
IgM positivity was more in the early febrile period between 6-10days.  
Chi square test =25.66 p < 0.0001(Significant) 
 
 
 
 
 
 
 
 
 
 
 TABLE - 9 SEASONAL DISTRIBUTION OF CHIKUNGUNYA 
CASES (n=62) 
Month / year Total number of suspected cases 
Total number of 
positive cases 
Percentage 
of patients 
October 2009 22 9 14.5 
November 2009 25 13 20.9 
December 2009 28 16 25.8 
January 2010 23 12 19.3 
February 2010 13 5 8.0 
March 2010 5 1 1.6 
April 2010 7 1 1.6 
May 2010 5 1 1.6 
June 2010 4 -- -- 
July 2010 6 2 3.2 
August 2010 4 -- -- 
September 2010 8 2  3.2 
 
The  incidence of chikungunya  is increased during  November to January , 
that is during monsoon and post monsoon period. 
 
     
 
 TABLE - 10 DISTRIBUTION OF CHIKUNGUNYA CASES WITH 
COINFECTION (n=62) 
 
DENGUE IgM positive Lepto MSAT positive Total 
Chikungunya IgM 
positive 
5 6 11 
 
Dengue co-infection and Leptospiral  co-infections were identified. 
 
TABLE - 11  DENGUE SERO POSITIVITY 
 
Dengue co-infection with chikungunya was 8%. 
 
TABLE - 12 LEPTO SERO POSITIVITY 
Total no of samples LEPTO MSAT  positives Percentage 
150 6 9 
 
Leptospiral  co-infection with chikungunya was 9%. 
 
 
 
 
 
 
Total no of samples DENGUE IGM positive Percentage 
150 5 8 
 TABLE - 13 RESULTS OF RT-PCR SAMPLES 
Total no of 
samples RT-PCR  negatives RT-PCR  positives Percentage 
40 21 19 47.5 
 
RT-PCR was found to be positive in nineteen samples out of forty samples 
(47.5%). 
TABLE – 14  CORRELATION OF CHIK  IgM  AND RT-PCR 
RESULTS (n=40) 
 RT-PCR  positives 
(n=19) 
Percentage 
RT-PCR  
negatives 
(n=21) 
Percentage 
Chikungunya chik 
IgM positive 
(n=16) 
7 17.5 9 22.5 
Chikungunya chik 
IgM negative 
(n=24) 
12 30 12 30 
 
PCR test positive for 12 samples (30%) which were negative by IgM capture 
ELISA. 
PCR  test positive for 7 samples (17.5%) which were positive by IgM 
capture ELISA. 
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 DISCUSSION 
Chikungunya has been increasingly recognised as an emerging 
infectious disease affecting  large number of people and produced one of the 
biggest outbreaks  in 2006. 
The high prevalence of Chikungunya cases at Chennai in the recent 
years, makes it necessary to evaluate the incidence of Chikungunya and to 
find out the seropositivity of Chikungunya cases. 
Rapid diagnosis of Chikungunya is crucial for proper patient care and 
effective vector control measures. As IgM antibodies appear  early during 
the disease course, its detection is a valuable tool for rapid diagnosis. 
This study was done with 150 serum samples from patients with 
clinical symptoms suggestive of Chikungunya. 
The incidence of Chikungunya fever in this study over a period of one 
year (from October 2009 to September 2010) was 0.49%.[Table:1] among 
fever cases attending the fever clinic and those admitted in our hospital. 
The seropositivity of chikungunya cases [Table:2] in the present study 
among clinically suspected fever cases was 41.33%. The study conducted by 
Suryawanshi et al in 2006 in Maharashtra showed  a seropositivity of 
chikungunya cases  of  52.4%.(80)  
 The higher distribution of chikungunya cases in the present study was 
seen in the 29-40 year age group (48.5%) (Table:3) followed by 40-60 years 
age group (42.5%) This was similar to the study conducted by Suryawanshi 
et al in 2006 in Maharashtra which showed 63% of cases in less than 30 
years age group.(82) 
                In the present study, Chikungunya was found more among female 
patients (42.8%) as compared to male patients (38.9%) (Table-4). This is 
similar to the study done by Thiruvenkadam et al in 2006 in Chennai  which 
showed more number of  Chikungunya cases in female patients (66.6%).(82) 
The predominant symptoms with which  patients presented in the 
present study (Table -5) were arthralgia (100%), fever (96.7%), joint 
swelling (75.8%), rash (59.7%), itching (53.2%), conjunctival congestion 
(33.9%), cough (8%), vomiting (4.8%). In the study conducted by 
Thiruvenkadam et al in 2006, the predominant symptoms were fever 
(91.2%), headache (94.8%), myalgia (95.2%), arthralgia (92.8%), neck 
stiffness (41%), edema (24.2%), rashes (2.6%). There was no associated case 
fatality in both the studies.(82)  In a study conducted by Suryawanshi et al in 
2006, the predominant symptoms were fever (100%), joint swelling (100%), 
headache (48%) and rash (27%).(80)  
In the present study, maximum cases were reported in the month of 
November and December [Table-8]. In the study conducted by Suryawanshi 
 et al in 2006, maximum cases were reported in the month of August.(82 ) The 
incidence of chikungunya is higher following rainfall. True to this, a clear 
cut incidence of  chikunguya cases was seen between September to 
December when TamilNadu receives rainfall from North East monsoon and 
post monsoon period. 
In the present study maximum number of cases ( 69.3%) of 
chikungunya  were from Chennai District, followed by Vellore (16.1%),  
Tiruvallur(8%) and Kanchipuram(6.4%) (Table-7).   As this is tertiary care 
centre situated in Chennai, patients were more from in around  Chennai. 
In the present study, Dengue coinfection with the  Chikungunya cases 
was 8% (Table -11).This is similar to the study conducted by Yergolkar et al 
in 2006. Another study which reported 3% Dengue coinfection with 
Chikungunya was conducted by Carey DE et al in 1964.(14 )  This is due to 
the fact that the same vector Aedes transmits  both Chikungunya  and 
Dengue viruses. 
In this present study, Leptospiral  co-infection in Chikungunya cases 
was  4.6% (Table-12).There was no study conducted for Leptospiral co-
infection  to compare the results.  
 
 
 In the present study 92% of the patients presented with platelet count 
of  more than one lakh (Table-6).  This is similar to the findings in the study 
conducted by Thiruvenkatam  et al in 2006.(82) 
In this present study IgM capture ELISA for chikugunya positivity 
was more in the early  febrile period(Table-9). IgM antibodies were detected 
in  41.33% of the samples. In a study conducted by Suryawanshi et al in 
2006, showed 52.4% of IgM positivity.(82)  
RT-PCR was done using  primer targeting E1 and E2  genes to detect  
ECSA  phylogroup  for 40 samples in the early febrile period . 16  samples 
which were negative by IgM capture  ELISA  and  24  samples positive by 
IgM capture ELISA were subjected to RT-PCR. Nineteen samples were 
positive by  RT-PCR (47.5%) (Table-13). Among IgM positive cases 56% of 
cases were RT-PCR negative (Table-14). This could be due to the decrease 
in the viral load because of seroconversion.(58)   Out of RT-PCR positive 
cases, 63.1% were IgM negative showing that RT-PCR could diagnose early 
cases of Chikungunya  even before seroconversion. From this it is inferred 
that RT-PCR is more sensitive than IgM capture ELISA for samples 
collected in the early febrile period.(53)  
  The RT-PCR technique was useful in detecting the viral infection in 
the acute phase and also indicates the usefulness of molecular techniques in 
an outbreak scenario. A  report  by Lewthweite et al in 2009  highlighted the 
 importance of PCR in early detection of CHIKV Central Nervous System  
infections.(40)   PCR is also useful in tracing the evolution of the virus by 
phylogenetic analysis .  PCR is a more sensitive method for detection of the 
virus in the first week of disease onset.  Further studies on CHIKV that 
correlate molecular diagnostics with disease onset and progression may 
provide a better understanding. 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
• 150 clinically suspected cases of chikungunya were included in the study. 
• IgM capture ELISA, Reverse Transcriptase PCR for Chikungunya, Rapid 
dengue Duo cassette method, MSAT for Leptospirosis  tests were done 
for the suspected cases. 
• Arthralgia was most common presenting symptom(100%)  followed by 
fever (96.7%), joint swelling (75.8%), Rash (59.7%), Itching (53.2%), 
conjuctival congestion (33.9%), cough (8%)  and vomiting (4.8%). 
• Incidence of chikungunya among fever patients in the study  was 0.49%. 
• Preponderance of chikungunya was found in females (62.9%), 
males(37.1%). 
• Out of 150 samples tested, 62 (41.33%) patients were found to be positive 
for IgM antibodies  in the early and late febrile period. 
• Increased incidence of chikungunya was found during September to 
January months, during monsoon and post monsoon period. 
• Increased number of cases of chikungunya were from Chennai followed 
by Vellore, Kanchipuram and Tiruvallur. 
• RT-PCR was positive for nineteen patients with symptoms of 
chikungunya. 
• Dengue co-infection with chikungunya cases was  8%. 
• Leptospiral co-infection with chikungunya was 9%. 
 CONCLUSION 
 
• The incidence of chikungunya was 0.49% among patients attending 
the fever clinic and patients admitted in Government General Hospital, 
Chennai. 
• The seropositivity of chikungunya cases was  41.33%. 
• Dengue co-infection with chikungunya was 8%. 
• Leptospiral  co-infection with chikungunya was 9%. 
• RT-PCR  positivity among forty patients  was 47.5%. 
• Serum samples need to be collected at a very early period (1-3 days) 
within onset of fever to determine the serotype by RT-PCR. 
• Serological diagnosis should be done in all clinically suspected 
Chikungunya cases to help in early initiation of treatment, thereby, 
minimizing the morbidity. 
 
 
 
 
 
 
 
 PROFORMA 
 
• Name:                                                                               IP/OP no. 
• Age:                                                                                   Ward: 
• Sex: 
• Occupation: 
• Address: 
• Economic status: 
• Fever 
• Joint pains 
• Chills 
• Headache 
• Vomiting 
• Joint swelling 
• Low back pain 
• Rash 
• Photophobia 
• Retro orbital pain 
• Abdominal pain 
• Examination 
• Site of joint pain 
• Icterus 
 
Investigations 
 CHIK IgM capture ELISA 
 RT – PCR 
 MSAT 
 Dengue rapid duo cassette method 
 
 
 
 BIBLIOGRAPHY 
1. Bandyopadhyay B, Bandyopadhyay D, Bhattacharya R, De R, Saha B, 
Mukherjee H, et al. Death due to chikungunya. Trop Doct. 
2009;39:187–8.  
2. Bandyopadhyay B, Pramanik N, De R, Mukherjee D, Mukherjee H, 
Neogi DK, et al. Chikungunya in West Bengal, India. Trop Doct. 
2009;39:59–60. 
3. Bandyopadhyay D, Ghosh SK. Mucocutaneous features of 
Chikungunya fever: a study from an outbreak in West Bengal, India. 
Int J Dermatol. 2008;47:1148–52.  
4. Benjamin M. Chikungunya is not a Swahili word, it is from the 
Makonde language! Available from: 
http://kamusiproject.org/en/node/144.  
5. Bhatia R, Narain JP. Re-emerging chikungunya fever: some lessons 
from Asia. Trop Med Int Health. 2009;14:940–6. Epub 2009 Jun 28.  
6. Bhavana K, Tyagi I, Kapila RK. Chikungunya virus induced sudden 
sensorineural hearing loss. Int J Pediatr Otorhinolaryngol. 
2008;72:257-9.  
 7. Bodenmann P, Genton B. Chikungunya: an epidemic in real time. 
Lancet. 2006;368:258.  
8. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, 
et al. Persistent arthralgia associated with chikungunya virus: A study 
of 88 adult patients on reunion island. Clin Infect Dis. 2008;47:469–
75. 
9. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, 
Becquart JP, et al. Outbreak of chikungunya on Reunion Island: Early 
clinical and laboratory features in 157 adult patients. Clin Infect Dis. 
2007;44:1401–7.  
10. Bouquillard E, Combe B. Rheumatoid arthritis after Chikungunya 
fever: A prospective follow-up study of 21 cases. Ann Rheum Dis. 
2009;68:1505–6. 
11. Brighton SW. Chloroquine phosphate treatment of chronic 
Chikungunya arthritis. An open pilot study. S Afr Med J. 
1984;66:217-8.  
12. Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus 
infection. A retrospective study of 107 cases. S Afr Med J. 
1983;63:313–5.  
 13. Brighton SW, Simson IW. A destructive arthropathy following 
Chikungunya virus arthritis-a possible association. Clin Rheumatol. 
1984;3:253–8.  
14. Centers for Disease Control and Prevention (CDC) Chikungunya fever 
diagnosed among international travelers - United States, 2005-2006. 
MMWR Morb Mortal Wkly Rep. 2006;55:1040–2.  
15. Chahar HS, Bharaj P, Dar L, Guleria R, Kabra SK, Broor S. Co-
infections with chikungunya virus and dengue virus in Delhi, India. 
Emerg Infect Dis. 2009;15:1077–80.   
16. Chandak NH, Kashyap RS, Kabra D, Karandikar P, Saha SS, Morey 
SH, et al. Neurological complications of Chikungunya virus infection. 
Neurol India. 2009;57:177–80.  
17. Chevillon C, Briant L, Renaud F, Devaux C. The Chikungunya threat: 
an ecological and evolutionary perspective. Trends Microbiol. 
2008;16:80–8.  
18. Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel- 
Benhassine F, Touret Y, Barau G, et al 2008 A mouse model for 
Chikungunya: Young age and ineffi cient type-I interferon signaling 
are risk factors for severe disease. 
 19. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, 
Flahault A, et al. On chikungunya acute infection and chloroquine 
treatment. Vector Borne Zoonotic Dis. 2008;8:837–9.  
20. De Lamballerie X, Leroy E, Charrel RN, Ttsetsarkin K, Higgs S, 
Gould EA. Chikungunya virus adapts to tiger mosquito via 
evolutionary convergence: a sign of things to come? Virol J. 
2008;5:33.  
21. Directorate of National Vector Borne Disease Control Pogramme. 
Status report on Dengue and Chikungunya as on 30.06.09. Available 
from: http://nvbdcp.gov.in/Doc/den-chikun-report-june09.pdf 
22. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann 
O, Quenel P, et al. Atypical Chikungunya virus infections: Clinical 
manifestations, mortality and risk factors for severe disease during the 
2005-2006 outbreak on Réunion. Epidemiol Infect. 2009;137:534–41.  
23. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, 
Mangiafico JA. Phase II safety and immunogenicity study of live 
chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 
2000;62:681–5.  
24. Fourie ED, Morrison JG. Rheumatoid arthritic syndrome after 
chikungunya fever. S Afr Med J. 1979;56:130–2. 
 25. Fradin MS,Day JF. Comparative efficacy of insect repellents against 
mosquito bite. N Engl J Med, 2002; 347:13-18. 
26. Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker 
G, et al. Multidisciplinary prospective study of mother-to-child 
chikungunya virus infections on the island of La Réunion. PLoS Med. 
2008;5:E60.  
27. Grivard P, Le Roux K, Laurent P, Fianu A, Perrau J, Gigan J, et al. 
Molecular and serological diagnosis of Chikungunya virus infection. 
Pathol Biol (Paris) 2007;55:490–4. 
28. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, 
infection, and disease: a cross-disciplinary review. Clin Microbiol 
Rev. 2001;14:909–32.   
29. Inamadar AC, Palit A, Sampagavi VV, Raghunath S, Deshmukh NS. 
Cutaneous manifestations of chikungunya fever: Observations made 
during a recent outbreak in south India. Int J Dermatol. 2008;47:154–
9.  
30. Jadhav M, Namboodripad M, Carman RH, Carey DE, Myers RM. 
Chikungunya disease in infants and children in Vellore: a report of 
clinical and haematological features of virologically proved cases. 
Indian J Med Res. 1965;53:764–76.  
 31. Johnson DF, Druce JD, Chapman S, Swaminathan A, Wolf J, 
Richards JS, et al. Chikungunya virus infection in travellers to 
Australia. Med J Aus. 2008;188:41–3. 
32. Jupp PG, McIntosh BM. Chikungunya virus disease. In: Monath TP, 
editor. The arboviruses: epidemiology and ecology. Vol II. Boca 
Raton: CRC Press; 1988. pp. 137–57. 
33. Kannan M, Rajendran R, Sunish IP, Balasubramaniam R, 
Arunachalam N, Paramsivan R, et al. A study on chikungunya 
outbreak during 2007 in Kerala, south India. Indian J Med Res. 
2009;129:311–5.  
34. Kennedy AC, Fleming J, Solomon L. Chikungunya viral arthropathy: 
A clinical description. J Rheumatol. 1980;7:231–6. 
35. Khan AH, Morita K Del Carncn Parquit M, Hasebe F, Matchenge EG, 
Igarashi A. Complete neucleotide sequence of Chikungunya  virus and 
evidence for aninternal polyadenylation site. J. Gen. Virology 2002; 
83: 3075-84. 
36. Lakshmi V, Neeraja M, Subbalaxmi MV, Parida MM, Dash PK, 
Santhosh SR, et al. Clinical features and molecular diagnosis of 
Chikungunya fever from South India. Clin Infect Dis. 2008;46:1436–
42.  
 37. Lakshmipathy DT, Dhanasekaran D. Molecular epidemiology of 
Chikungunya virus in Vellore district, Tamilnadu, India in 2006. East 
Afr J Public Health. 2008;5:122–5. 
38. Lenglet Y, Barau G, Robillard PY, Randrianaivo H, Michault A, 
Bouveret A, et al. Chikungunya infection in pregnancy: Evidence for 
intrauterine infection in pregnant women and vertical transmission in 
the parturient. Survey of the Reunion Island outbreak. J Gynecol 
Obstet Biol Reprod (Paris) 2006;35:578–83.  
39. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Jr, Lupton 
HW. Development of an attenuated strain of chikungunya virus for 
use in vaccine production. Vaccine. 1986;4:157–62.  
40. Lewthwaite P, Vasanthapuram R, Osborne JC, Begum A, Plank JL, 
Shankar MV, et al. Chikungunya virus and central nervous system 
infections in children, India. Emerg Infect Dis. 2009;15:329–31.  
41. Lumsden WH. An epidemic of virus disease in Southern Province, 
Tanganyika Territory, in 1952-53; II. General description and 
epidemiology. Trans R Soc Trop Med Hyg. 1955;49:33–57. ] 
42. Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu 
RB, et al. Ocular manifestations associated with chikungunya. 
Ophthalmology. 2008;115:287–91.  
 43. Mahesh G, Giridhar A, Shedbele A, Kumar R, Saikumar SJ. A case of 
bilateral presumed chikungunya neuroretinitis. Indian J Ophthalmol. 
2009;57:148–50.  
44. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. 
Increased mortality rate associated with chikungunya epidemic, 
Ahmedabad, India. Emerg Infect Dis. 2008;14:412–5 
45. Mavalankar D, Shastri P, Raman P. Chikungunya epidemic in India: A 
major public-health disaster. Lancet Infect Dis. 2007;7:306–7.  
46. Mittal A, Mittal S, Bharathi JM, Ramakrishnan R, Sathe PS. Uveitis 
during outbreak of Chikungunya fever. Ophthalmology. 
2007;114:1798. 
47. Mohan A. Chikungunya fever: clinical manifestations & management. 
Indian J Med Res. 2006;124:471–4.  
48. Mohan A. Chikungunya fever strikes in Andhra Pradesh. Natl Med J 
India. 2006;19:240. 
49. Mohan A, Sharma SK. Chikungunya fever. In: Singal RK, editor. 
Medicine update. Mumbai: Association of Physicians of India; 2007. 
pp. 634–8. 
 50. Mourya DT, Thakare JR, Gokhale MD, Powers AM, Hundekar SL, 
Jayakumar PC, et al. Isolation of chikungunya virus from Aedes 
aegypti mosquitoes collected in the town of Yawat, Pune District, 
Maharashtra State, India. Acta Virol. 2001;45:305–9.  
51. Muyembe-Tamfum JJ, Peyrefitte CN, Yogolelo R, Mathina Basisya E, 
Koyange D, Pukuta E, et al. Epidemic of Chikungunya virus in 1999 
and 2000 in the Democratic Republic of the Congo. Med Trop (Mars) 
2003;63:637–8.  
52. National Institute of Communicable Disease, New Delhi. 
Chikungunya fever. CD Alert. 2006;10:6–8. 
53. Nimmannitya S,Halstead SB, Cohen SN, Margiotta MR. Dengue and 
chikungunya virus infection in man in Thailand, 1962-1964. I. 
Observations on hospitalized patients with hemorrhagic fever.  Am J 
Trop Med Hyg. 1969;18:954–71.  
54. Obeyesekere I, Hermon Y. Myocarditis and cardiomyopathy after 
arbovirus infections (dengue and chikungunya fever) Br Heart J. 
1972;34:821–7.  
55. Obeyesekere I, Hermon Y. Arbovirus heart disease: myocarditis and 
cardiomyopathy following dengue and chikungunya fever—a follow-
up study. Am Heart J. 1973;85:186–94.  
 56. Padbidri VS, Gnaneswar TT. Epidemiological investigations of 
chikungunya epidemic at Barsi, Maharashtra state, India. J Hyg 
Epidemiol Microbiol Immunol. 1979;23:445–51. 
57. Paramasivan R, Philip Samuel P, Thenmozhi V, Rajendran R, Victor 
Jerald Leo S, Dhananjeyan KJ, et al. Chikungunya virus isolated in 
Lakshadweep islands in the Indian Ocean: Evidence of the 
Central/East African genotype. Jpn J Infect Dis. 2009;62:67–9.  
58. Pastorino B, Bessaud M, Grandadam M, Murri S, Tolou HJ, Peyrefitte 
CN. Development of a TaqMan RT-PCR assay without RNA 
extraction step for the detection and quantification of African 
Chikungunya viruses. J Virol Methods. 2005;124:65–71.  
59. Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an 
epidemic arbovirosis. Lancet Infect Dis. 2007;7:319–27.  
60. Pistone T, Ezzedine K, Schuffenecker I, Receveur MC, Malvy D. An 
imported case of Chikungunya fever from Madagascar: use of the 
sentinel traveller for detecting emerging arboviral infections in 
tropical and European countries. Travel Med Infect Dis. 2009;7:52–4. 
61. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-
emergence of a zoonotic arbovirus. J Gen Virol. 2007;88:2363–77.  
 62. Rampal, Sharda M, Meena H. Neurological complications in 
Chikungunya fever. J Assoc Physicians India. 2007;55:765–9. 
63. Rampal, Sharda M, Meena H. Hypokalemic paralysis following 
Chikungunya fever. J Assoc Physicians India. 2007;55:598.  
64. Reiskind MH, Pesko K, Westbrook CJ, Mores CN. Susceptibility of 
Florida mosquitoes to infection with chikungunya virus. Am J Trop 
Med Hyg. 2008;78:422–5.  
65. Rishnamoorthy K, Harichandrakumar KT, Krishna Kumari A, Das 
LK. Burden of chikungunya in India: estimates of disability adjusted 
life years (DALY) lost in 2006 epidemic. J Vector Borne Dis. 
2009;46:26–35. 
66. Robillard PY, Boumahni B, Gérardin P, Michault A, Fourmaintraux 
A, Schuffenecker I, et al. Vertical maternal fetal transmission of the 
chikungunya virus. Ten cases 84 among pregnant women. Presse Med. 
2006;35:785–8.  
67. Robinson MC. An epidemic of virus disease in Southern Province, 
Tanganyika Territory, in 1952-53; I. Clinical features. Trans R Soc 
Trop med Hyg. 1955;49:28–32. 
 
 68. Rodrigues FM, Patankar MR, Banerjee K, Bhatt PN, Goverdhan MK, 
Pavri KM, et al. Etiology of the 1965 epidemic of febrile illness in 
Nagpur city, Maharashtra State, India. Bull World Health Organ. 
1972;46:173–9.  
69. Rulli NE, Suhrbier A, Hueston L, Heise MT, Tupanceska D, Zaid A, 
et al. Ross River virus: molecular and cellular aspects of disease 
pathogenesis. Pharmacol Ther. 2005;107:329–42.  
70. Sam IC, AbuBakar S. Chikungunya virus infection. Med J Malaysia. 
2006;61:264–9.  
71. Samuel PP, Krishnamoorthi R, Hamzakoya KK, Aggarwal CS. 
Entomo-epidemiological investigations on chikungunya outbreak in 
the Lakshadweep islands, Indian Ocean. Indian J Med Res. 
2009;129:442–5. 
72. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney 
MC, et al. Genome microevolution of chikungunya viruses causing the 
Indian Ocean outbreak. PLoS Med. 2006;3:e263.  
73. Sebastian MR, Lodha R, Kabra SK. Chikungunya infection in 
children. Indian J Pediatr. 2009;76:185–9.   
 74. Shah KV, Gibbs CJ, Jr, Banerjee G. Virological investigation of the 
epidemic of haemorrhagic fever in Calcutta: isolation of three strains 
of Chikungunya virus. Indian J Med Res. 1964;52:676–83.  
75. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, 
et al. Chikungunya infection: an emerging rheumatism among 
travelers returned from Indian Ocean islands. Report of 47 cases. 
Medicine (Baltimore) 2007;86:123–37. 
76. Simon F, Savini H, Parola P. Chikungunya: a paradigm of emergence 
and globalization of vector-borne diseases. Med Clin North Am. 
2008;92:1323–43. 
77. Singh SS, Manimunda SP, Sugunan AP, Sahina, Vijayachari P. Four 
cases of acute flaccid paralysis associated with chikungunya virus 
infection. Epidemiol Infect. 2008;136:1277–80 
78. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine 
F, Rudnicka D, et al. Characterization of reemerging chikungunya 
virus. PLoS Pathog. 2007;3:E89.   
79. Sudeep AB, Parashar D. Chikungunya: an overview. J Biosci. 
2008;33:443–9.  
 
 80. Suryawanshi SD, Dube AH, Khadse RK, Jalgaonkar SV, Sathe PS, 
Zawar SD, et al. Clinical profile of chikungunya fever in patients in a 
tertiary care centre in Maharashtra, India. Indian J Med Res. 
2009;129:438–41.  
81. Tandale BV, Sathe PS, Arankalle VA, Wadia RS, Kulkarni R, Shah 
SV, et al. Systemic involvements and fatalities during Chikungunya 
epidemic in India, 2006. J Clin Virol. 2009;46:145–9. 
82. Thiruvengadam KV, Kalyanasundaram V, Rajgopal J. Clinical and 
pathological studies on chikungunya fever in Madras city. Indian J 
Med Res. 1965;53:729–44. 
83. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single 
mutation in chikungunya virus affects vector specificity and epidemic 
potential. PLoS Pathog. 2007;3:e201.   
84. Valamparampil JJ, Chirakkarot S, Letha S, Jayakumar C, Gopinathan 
KM. Clinical profile of Chikungunya in infants. Indian J Pediatr. 
2009;76:151–5 
85. Wadia RS. A neurotropic virus (Chikungunya) and a neuropathic 
aminoacid (homocysteine) Ann Indian Acad Neurol. 2007;10:198–
213. 
 86. World Health Organization. Outbreak news. Chikungunya and 
dengue, south-west Indian Ocean. Wkly Epidemiol Rec. 2006;81:106–
8. 
87. World Health Organization Regional Office for South-East Asia. 
Chikungunya fever, a re-emerging disease in Asia. Available from: 
http://www.searo.who.int/en/Section10/Section2246.htm. 
88. World Health Organization, Regional Office for South-East Asia. 
Guidelines for prevention and control of Chikungunya fever. New 
Delhi: World Health Organization, Regional Office for South-East 
Asia; 2009.  
89. World Health Organization, Regional Office for South-East Asia. 
Proposed case definition of Chikungunya fever. Available from: 
http://www.searo.who.int/LinkFiles/Chikungunya_Def_Chikungunya_
Fever.pdf  
90. Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, 
Gandhe SS, et al. Chikungunya outbreaks caused by African genotype, 
India. Emerg Infect Dis. 2006;12:1580–3.  
 
 
